Understanding bone remodeling and how current
therapies affect remodeling allows for a rational
approach to pharmacologic intervention, with a predictable end-point of reducing the fracture rate. As
newer antiresorptive and anabolic agents are developed,
further decreases in fracture rate should be anticipated.
In addition, models of care such as the FLS concept
should be implemented nationally to screen, diagnose,
and provide earlier treatment for those with fragility
fractures and risk of further fracture